Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2017-03-29
2020-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Molecular Biomarkers in Periocular Adnexal Tumours
NCT06080009
ctDNA in Cutaneous Squamous Cell Carcinoma
NCT06875609
Skin Tumor Biomarkers by Mass Spectrometry Imaging
NCT06227416
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
NCT01209299
Interest and Impact of Skin Cancer Genetic Testing
NCT02941900
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-arm, 500 participates
Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* above 18 years old
Exclusion Criteria
* pregnant women
* children or person without judgment ability
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
DR Dean Ad EL, MD
Role: PRINCIPAL_INVESTIGATOR
Rabin Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RabinMC
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
DR Asaf Olshinka, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Winder M, Viros A. Mechanisms of Drug Resistance in Melanoma. Handb Exp Pharmacol. 2018;249:91-108. doi: 10.1007/164_2017_17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0515-15-RMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.